What is seronegative neuromyelitis optica spectrum disorder?

被引：0
|
作者：
Gibbons, E. [1 ]
Campagna, G. [1 ]
O'Connell, K. [2 ]
Yeo, T. [2 ]
Whittam, D. [1 ]
Leite, M. [2 ]
Palace, J. [3 ]
Jacob, A. [1 ]
Huda, S. [1 ]
机构：
[1] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England
[2] John Radcliffe Hosp, Oxford, England
[3] Univ Oxford, Oxford, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0761
引用
收藏
页码：482 / 482
页数：1
相关论文
共 50 条
  • [31] CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage
    Jae-Won Hyun
    Yeseul Kim
    Ki Hoon Kim
    Su-Hyun Kim
    Mads Nikolaj Olesen
    Nasrin Asgari
    Sasitorn Siritho
    Friedemann Paul
    Ho Jin Kim
    Journal of Neuroinflammation, 19
  • [32] Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
    Sato, Douglas Kazutoshi
    Callegaro, Dagoberto
    Lana-Peixoto, Marco Aurelio
    Nakashima, Ichiro
    Fujihara, Kazuo
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2014, 72 (06) : 445 - 450
  • [33] Intractable cough as characteristic symptom of neuromyelitis optica and neuromyelitis optica spectrum disorder
    Fujita-Nakata, M.
    Tomioka, R.
    Tanaka, K.
    Nakanishi, M.
    Nagayama, S.
    Takahashi, R.
    Machiya, T.
    Hamada, T.
    Matsui, M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (04) : 576 - 577
  • [34] Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data
    Altintas, A.
    Karabudak, R.
    Balci, B. Petek
    Terzi, M.
    Soysal, A.
    Saip, S.
    Kurne, A. Tuncer
    Uygunoglu, U.
    Nalbantoglu, M.
    Gozubatik-Celik, G.
    Isik, N.
    Celik, Y.
    Gokcay, F.
    Duman, T.
    Boz, C.
    Yucesan, C.
    Celebisoy, N.
    Diker, S.
    Isikay, I. C.
    Kansu, T.
    Siva, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 824 - 825
  • [35] Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
    Collongues, N.
    Marignier, R.
    Jacob, A.
    Leite, M. I.
    Sivas, A.
    Paul, F.
    Zephir, H.
    Akman-Demirs, G.
    Elsone, L.
    Jarius, S.
    Papeix, C.
    Mutch, K.
    Saips, S.
    Wildemann, B.
    Kitley, J.
    Karabudak, R.
    Aktas, O.
    Kuscu, D.
    Altintas, A.
    Palace, J.
    Confavreux, C.
    De Seze, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (08) : 1086 - 1094
  • [36] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [37] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [38] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [39] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [40] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
12345